In mice fed an 8% high-salt diet, Lactobacillus plantarum CCFM639 lowered radiotelemetry-measured blood pressure, preserved gut barrier integrity, partly corrected dysbiosis, and calmed ileal inflammation. The probiotic cut IL-6, blocked the IL-22/STAT3/SAA pathway, and curbed Th17 activation and IL-17A output. Neutralizing IL-17A alone reproduced the benefit, improving endothelium-dependent relaxation while lowering eNOS Thr495 phosphorylation and RhoA expression. In hypertensive patients with high urinary sodium, supplementation reduced blood pressure, and larger falls in serum IL-17A tracked with larger pressure drops.
The mechanistic chain here is unusually tidy: gut Th17 cells have already been linked to salt-sensitive hypertension, and this work ties a specific probiotic strain to that axis, then confirms causality with antibody neutralization. That is stronger than most probiotic-blood-pressure claims, which rest on associations. The core evidence, though, comes from mice on an extreme 8% salt diet, so the dose-response to realistic human intake is unknown. The human component appears small and, from the abstract, may lack rigorous placebo control or long-term follow-up. The IL-17A correlation in patients shows association, not proof the same pathway drives the effect. Probiotic meta-analyses show average systolic reductions of only a few mmHg, and strain specificity means results from CCFM639 cannot be generalized to yoghurt or other Lactobacillus products. Nothing here replaces cutting sodium or standard antihypertensives. Treat it as a promising, mechanistically credible adjunct hypothesis that needs a large, placebo-controlled trial before anyone should buy it for blood pressure.